Final prespecified analysis of the phase III LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy ☆

Annals of Vascular Surgery · Elsevier

Аннотация

Publication date: Available online 25 October 2026 Source: Annals of Oncology Author(s): D.Y.C. Heng, M. Schmidinger, R. McDermott, S.H. Park, M. Burotto, C. Ciccarese, E. Verzoni, C. Suárez, M. Eto, H.J. Cutuli, C. Porta, R. Manneh Kopp, S. Rottey, G. de Velasco, B.P. Valderrama, A.A. Azad, U. De Giorgi, M. Pavic, P. Tomczak, R. Figlin

Читать у издателя →

Похожие статьи